Excellent
PT-141
PT-141 is a peptide therapy that enhances sexual arousal and performance by directly stimulating the brain’s arousal pathways.
Increases sexual arousal & desire
Works independently of hormones
Rapid, on demand results
Safe, non-addictive, and well tolerated
* Price reflects a 6-month treatment plan
Unlike medications that work on blood vessels, PT-141 activates melanocortin receptors in the central nervous system, specifically targeting areas that influence sexual desire and arousal. By engaging these neural pathways, it improves sexual responsiveness in both men and women. This unique mechanism allows it to enhance libido without relying solely on increased blood flow.
PT-141 was derived from research on Melanotan II in the 1990s, when scientists noted its unexpected effects on sexual arousal. Developed further as Bremelanotide, it underwent multiple clinical trials to assess safety and efficacy for sexual dysfunction. In 2019, the FDA approved it for premenopausal women with hypoactive sexual desire disorder (HSDD), marking it as the first-of-its-kind therapy. Studies continue to explore its broader potential in addressing sexual dysfunction across different populations.
Reported side effects may include temporary nausea, flushing, or headache, with some individuals experiencing mild increases in blood pressure. These effects are usually short-lived and resolve on their own.
See the Science
PT-141: a melanocortin agonist for the treatment of sexual dysfunction2003
Double-blind, placebo-controlled evaluation of the safety and pharmacokinetics of PT-141 in healthy and ED subjects2004
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder — Phase 3 Trials in Premenopausal Women2019
An Overview of Preclinical CNS Effects on Female Sexual Function (PT-141/Bremelanotide)2007
Two-drug combination shows positive results in men with ED: co-administration of PT-141 and Sildenafil2005
Key Takeaways
Central Arousal Activation
Clinically Proven Results
Fast-Acting & Flexible
Restores Confidence & Connection
Frequently asked questions
Yes, PT-141 is FDA-approved only for premenopausal women with HSDD. It has not been approved for men, but has been used off-label as it activates the same brain pathways that regulate sexual desire in both sexes. Early data suggest it may improve libido and arousal in men.
Yes, PT-141 has undergone multiple large-scale clinical trials, showing significant improvements in sexual desire and satisfaction compared to placebo.
PT-141 works by activating melanocortin receptors in the brain, which influence sexual desire, arousal, and motivation, addressing the mental component of intimacy rather than hormonal or vascular factors.
Yes, clinical trials show PT-141 is safe and well tolerated. The most common side effects include nausea, flushing, or mild headache, which typically lessen with continued use. Working with a licensed provider helps ensure proper monitoring and product quality.
Those with uncontrolled high blood pressure, heart disease, or who are pregnant or nursing should avoid PT-141 unless advised otherwise by a licensed provider.
PT-141 is most commonly taken as a single subcutaneous injection at least 45 minutes before sexual activity. It’s also available as a nasal spray, offering a needle-free, fast-acting alternative depending on patient preference.
Some providers integrate PT-141 into comprehensive sexual-wellness programs that address hormonal, physical, and psychological factors, but formal combination studies are limited. Any stack should be clinician-supervised.
How AIRA works
Medical Intake
Prescription
Delivery
Why AIRA?
Your body already holds the blueprint — AIRA helps you unlock it. Our physician-guided peptide programs will help you perform, recover, and feel your best.
Chat with a provider 24/7
Trusted pharmacy
Manage goals in one place
Fast, discreet shipping
Start your new AIRA today
Unleash a healthier, more energetic version of yourself with AIRA. Check out treatments now and embark on your journey to a fulfilling life.
